Clinical Trial Update: A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients [Phase 2]

View source ↗

Summary

A Phase II study of SSGJ-707 as first-line monotherapy for PD-L1 positive advanced non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SSGJ-707

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: NSCLC | Phase 2 | Status: RECRUITING